Automated Soluble Fibrin Assays Evaluated
By LabMedica International staff writers Posted on 26 Dec 2013 |
Image: Micrograph of acute thrombotic microangiopathy disseminated intravascular coagulation (Photo courtesy of Nephron).
The soluble fibrin monomer (sFM) assay has the potential to be used both as an aid in the diagnosis of disseminated intravascular coagulation (DIC) and as a thrombotic marker.
The sFM test differs from the D-dimer (Ddi) assay in that it detects a much earlier produced fragment produced only by thrombin action on fibrinogen, whereas Ddi is a much later produced fragment formed by plasmin cleavage of cross-linked fibrin.
Scientists at the Karolinska University Hospital (Solna, Sweden) compared two commercially available automated sFM assays in the routine hospital setting using samples obtained from the general hospital ward and the emergency room. The results obtained with the two automated assays were compared with each other and with the results obtained using the routine semiquantitative hemagglutination assay.
The study showed that both automated assays, the LIAtest sFM assay (Diagnostica Stago; Genevilliers, France) and the LPIA-Iatro SF assay (Mitsubishi Kagaku Bio-Clinical Laboratories; Tokyo, Japan) were analogous with each other. No patient sample previously classified as positive would be missed, but with the higher sensitivity in the automated tests, more samples are positive.
The authors concluded that both automated tests are suitable for routine laboratory use. Both assays had the advantage over the hemagglutination assay in that previously frozen samples could be used, and the assays are easier and quicker to perform. The LIA sFM Stago has slightly better sensitivity but has a tendency to lower specificity than the Iatro SF test. The study was published in the December 2103 issue of the International Journal of Laboratory Hematology.
Related Links:
Karolinska University Hospital
Diagnostica Stago
Mitsubishi Kagaku Bio-Clinical Laboratories
The sFM test differs from the D-dimer (Ddi) assay in that it detects a much earlier produced fragment produced only by thrombin action on fibrinogen, whereas Ddi is a much later produced fragment formed by plasmin cleavage of cross-linked fibrin.
Scientists at the Karolinska University Hospital (Solna, Sweden) compared two commercially available automated sFM assays in the routine hospital setting using samples obtained from the general hospital ward and the emergency room. The results obtained with the two automated assays were compared with each other and with the results obtained using the routine semiquantitative hemagglutination assay.
The study showed that both automated assays, the LIAtest sFM assay (Diagnostica Stago; Genevilliers, France) and the LPIA-Iatro SF assay (Mitsubishi Kagaku Bio-Clinical Laboratories; Tokyo, Japan) were analogous with each other. No patient sample previously classified as positive would be missed, but with the higher sensitivity in the automated tests, more samples are positive.
The authors concluded that both automated tests are suitable for routine laboratory use. Both assays had the advantage over the hemagglutination assay in that previously frozen samples could be used, and the assays are easier and quicker to perform. The LIA sFM Stago has slightly better sensitivity but has a tendency to lower specificity than the Iatro SF test. The study was published in the December 2103 issue of the International Journal of Laboratory Hematology.
Related Links:
Karolinska University Hospital
Diagnostica Stago
Mitsubishi Kagaku Bio-Clinical Laboratories
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms